Advertisement
Home »

Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States.

Jan 16, 2023

REFERENCES & ADDITIONAL READING

PubMed

ABOUT THE CONTRIBUTORS

  • Cristina Cano Garcia

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Goethe University Frankfurt, University Hospital Frankfurt, Department of Urology, Germany. Electronic address: cristina.canogarcia@kgu.de.

    Nancy Nimer

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Mattia Luca Piccinelli

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.

    Stefano Tappero

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, IRCCS Policlinico San Martino, Genova, Italy; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.

    Andrea Panunzio

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona.

    Francesco Barletta

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

    Reha-Baris Incesu

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

    Zhe Tian

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Fred Saad

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

    Anil Kapoor

    Division of Urology, McMaster Institute of Urology, McMaster University, Hamilton, Ontario, Canada.

    Alberto Briganti

    Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.

    Carlo Terrone

    Department of Urology, IRCCS Policlinico San Martino, Genova, Italy; Department of Surgical and Diagnostic Integrated Sciences (DISC), University of Genova, Genova, Italy.

    Shahrokh F Shariat

    Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, New York, USA; Department of Urology, University of Texas Southwestern, Dallas, Texas, USA; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.

    Derya Tilki

    Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.

    Alessandro Antonelli

    Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona.

    Ottavio De Cobelli

    Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.

    Luis A Kluth

    Goethe University Frankfurt, University Hospital Frankfurt, Department of Urology, Germany.

    Andreas Becker

    Goethe University Frankfurt, University Hospital Frankfurt, Department of Urology, Germany.

    Felix K H Chun

    Goethe University Frankfurt, University Hospital Frankfurt, Department of Urology, Germany.

    Pierre I Karakiewicz

    Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement